Table 3.
Abnormal serum chemistry and mean change in serum values from baseline to Week 12 in Norwegian patients with ankylosing spondylitis, stratified according to treatment group (celecoxib 200 or 400 mg daily [qd] or diclofenac 50 mg three times daily [tid]): safety population.
| Parameter | Celecoxib |
Diclofenac group | |
|---|---|---|---|
| 200 mg group | 400 mg group | ||
| C-reactive protein | |||
| N | 107 | 108 | 115 |
| Abnormal serum chemistry, baseline | 31 (29.0) | 41 (38.0) | 41 (35.7) |
| Abnormal serum chemistry, Week 12 | 32 (29.9) | 36 (33.3) | 36 (31.3) |
| Change from baseline to Week 12, mg/l | 0.8 ± 5.5 | −1.3 ± 12.3 | 0.7 ± 8.6 |
| N a | 99 | 102 | 107 |
| Alanine aminotransferase | |||
| N | 107 | 108 | 115 |
| Abnormal serum chemistry, baseline | 11 (10.3) | 10 (9.3) | 7 (6.1) |
| Abnormal serum chemistry, Week 12 | 11 (10.3) | 6 (5.6) | 21 (18.3) |
| Change from baseline to Week 12, U/l | −1.7 ± 12.9 | −1.8 ± 11.5 | 9.2 ± 20.0 |
| N a | 98 | 99 | 107 |
| Aspartate aminotransferase | |||
| N | 107 | 108 | 115 |
| Abnormal serum chemistry, baseline | 2 (1.9) | 1 (0.9) | 2 (1.7) |
| Abnormal serum chemistry, Week 12 | 3 (2.8) | 0 (0) | 2 (1.7) |
| Change from baseline to Week 12, U/l | −0.1 ± 7.6 | −0.6 ± 5.7 | 2.1 ± 8.6 |
| N a | 98 | 101 | 106 |
Data presented as: n or n (%) patients; mean ± SEM (change from baseline to Week 12).
a
Number of intention-to-treat patients with baseline and Week 12 measures.